Lioplim (filgrastim) / Abbott - LARVOL DELTA

NCCN has published updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) and the NCCN Drugs & Biologics Compendium (NCCN Compendium) for Hematopoietic Cell Transplantation, Version 1.2025. (NCCN)

NCCN guideline • Hematological Disorders • Oncology • Transplantation

Aphexda Plus Filgrastim Boosts Stem Cell Mobilization in Patients With Myeloma (Cure Today) - "'There was no doubt that when the two drugs were given together, the key important findings is that they were able to collect more stem cells in a shorter period of time than had we just use the (filgrastim). It's important to patients if they're going to go through a transplant to collect enough cells so that they can do a transplant. Typically we actually try to collect enough for two transplants in case we may do a second one either immediately or later,' Dr. Joseph Mikhael...explained in an interview with CURE."

Interview

Advances in the Management of Chemotherapy-Induced Neutropenia - Episode 13: CIN: Implications of the PROTECTIVE-2 Study (OncLive) - "Hope S. Rugo, MD, FASCO: It’s very interesting, and the mechanisms for understanding that I think are also fascinating. There was also a little bit of data on quality of life as well in patients who had received this....There has been the DUBLIN-3 trial, looking at non–small cell lung cancer and efficacy, which was presented at ESMO [European Society for Medical Oncology Congress] this year....but we can certainly use help in using checkpoint inhibitors in patients with breast cancer because even with our survival benefits in the metastatic setting, survival is still reasonably short. It will be interesting to see. I think this is a whole other area of investigation."

Video

Convenience, Cost Sway Choice of G-CSF Added to Chemo (Medscape) - "These results are 'practice reinforcing, in the sense that most prophylaxis, including G-CSF, is driven by preferences that depend on underlying clinical context,' commented Sandip P. Patel, MD...who was not involved in the survey. The results show that secondary prophylaxis 'is driven by efficacy,' whereas primary prophylaxis is driven by safety and/or cost 'to prevent a theoretical negative outcome,' which are 'reasonable preferences to have,' Patel told Medscape Medical News."

Media quote